Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.
LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.
Chief Executive Officer
Karsten Damgaard-Iversen, MBA
Karsten Damgaard-Iversen is an internationally accomplished business professional with over 30 years of global experience in the med-tech industry. He is a proven leader in operational and strategic management positions within large, medium and small healthcare technology companies. Karsten combines strong leadership skills and business acumen with in-depth technical and medical knowledge. He has served as a Board Director at Toshiba of Europe Ltd., Managing Director and Chief Group Executive at Toshiba Medical Systems Europe BV, Managing Director at Toshiba Medical Systems UK Ltd., CEO at SonoCine Inc., VP of International Operations at Fisher Imaging Corporation and Director of Sales & Marketing at Storz Medical AG. Karsten has also directly contributed to the invention and development of specific laser, ultrasound and x-ray based medical products. He holds an MBA from Emory University in Atlanta and a BSc in electronic engineering from Copenhagen University College.
Managing Director/ Chief Operations Officer
Erwin de Buijzer, MD, MBA
Erwin de Buijzer is the managing director of Humedics GmbH. After working as a medical doctor in ICU and surgery, he has held a number of positions at Eurotransplant and the Dutch Transplant Foundation. He has also worked in medical marketing for Abbott Laboratories and was the medical director at Nutricia Advanced Medical Nutrition. De Buijzer has an MBA from the Rotterdam School of Management in the Netherlands.
Dr. Ralf Kohnen
Ralf Kohnen is a well-known and respected senior executive in both German and global markets. After completing his PhD in Biology at Bochum University in 1992 he started his career out in field sales. Ralf rose steadily through the ranks over the next 20 years, including roles in product management, marketing and sales. Being a member of the executive committees of different global players over the past 13 years he managed marketing budgets of more than $30m., revenues in excess of $800m and more than 2500 staff, lastly as Executive Director China. During that period, he also took part in the International Executive Program at INSEAD in France and Singapore. Ralf worked for the multinational companies AstraZeneca, SanofiAventis and Novartis.
Finance & Controlling Manager
Kajo Wiest is Finance Manager of the Humedics GmbH and brings more than 15 years of finance and controlling experiences.
He was Director Controlling at Jerini AG. During his time at Jerini, he was responsible for the establishment of controlling structures as well as supporting the company’s IPO and the sale of its wholly-owned subsidiary JPT, where he served as Finance Manager afterwards.
Before he joined Humedics he worked as Director Finance& Controlling for Magforce AG.
Karin Dorrepaal is a member of the Triton Private Equity Industry Board in Frankfurt, and she also serves on a number of boards of pharmaceutical and functional food companies in Europe. Dorrepaal carried out research at the Netherlands Cancer Institute, and was previously a partner at Booz & Co (formerly, Booz Allen & Hamilton, now PWC), where she specialised in advising major pharmaceutical companies on strategy, sales, marketing and the supply chain.
Thomas Moeller is a general partner of BioMedPartners AG, which focuses on investments in life sciences in the DACH region. Thomas has been a venture capitalist for the last 17 years. Before joining BioMedPartners in 2003, he worked as Chief Financial Officer at NMT New Medical Technologies and as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.
Ute Mercker is the investment director of the life sciences team at IBB Beteiligungsgesellschaft, the regional venture capital fund of Berlin. She is responsible for IBB´s biotech and medtech portfolio, managing investments into companies such as Jerini and Scienion. She is deputy chair of the board at Scienion AG, and member of a number of other boards.
Dr. Annegret de Baey-Diepolder is a Venture Partner at Seventure Partners SA. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc..
As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings more than 15 years of experience in the life science and venture capital sector.
Dr. Christian Schneider is a managing partner of Vesalius Biocapital and has been a venture capital executive for more than 15 years, including time spent at PolyTechnos. He has worked in diagnostics, medtech, and therapeutics, including at Boehringer Mannheim/Roche, where he developed the first fully automated test for a new prostate cancer marker (free PSA), which is marketed by Roche worldwide.
Klaus Stoeckemann is a co-founder and managing partner of Peppermint VenturePartners, which focuses on investments in medical device and digital-health start-up companies in Germany and Europe. He is an experienced venture capitalist with more than 15 years of experience, including a role as a general partner at 3i Healthcare Venture Capital. Stoeckemann has also worked at Schering AG (now Bayer) and Asta Medica (Degussa), and is a member of the board of the German Association of Venture Capital (BVK).
Markus was Executive Vice President, Business Development, for GE Healthcare. Before GE, Markus worked as Head of Strategy, BD&L, and M&A for Novartis Molecular Diagnostics, and served as a member of the leadership team and as a member of the Cardiovascular & Metabolism Franchise Board for Novartis Pharma AG and the Global Business Development & Licensing group. Markus was CEO of two biotech start-ups, was Director of Business and Corporate Development at Schwarz Pharma and consultant at the Boston Consulting Group. Markus is also currently the Chief Business Officer of Ablynx.
Markus holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago.
Medical Advisory Board
|Prof. Dr. Peter Galle (Lead)|
|Prof. Dr. Hauke Lang|
|Prof. Dr. Guido Gerken|
|Prof. Dr. Hans J. Schlitt|
|Prof. Dr. Ali Canbay|
|Prof. Dr. Stefan Fichtner-Feigl|
Founders & Scientific Advisory Board
Karsten Heyne is one of the co-founders of Humedics GmbH. He is a Professor at the Free University of Berlin, with a focus on ultrafast spectroscopy in biologically-relevant systems. His research investigates electronic and structural changes as well as the specific manipulation of special organic molecule groups.
Martin Stockmann is one of the co-founders of Humedics GmbH, and continues to provide advice and support to the management team on medical-related issues. He works as an abdominal surgeon at the Berlin Charité University medical centre in Professor Neuhaus‘ department, and focuses on liver surgery and liver transplantation. He leads the Workgroup for the Liver, looking at improving recovery of patients after liver surgery and transplantation. Stockmann has published over 40 articles in the field of liver function testing.
Martin Stockmann, MD, PhD, an abdominal surgeon at the Berlin Charité University medical centre, created the LiMAx test in 2001 and founded the workgroup for the liver.
Karsten Heyne, a professor at the department of physics, Free University of Berlin, conducted the technical development of the LiMAx test.
Humedics was founded in 2009, and the company began development of the LiMAx prototype, with initial capital provided by the High Tech Gründerfonds. Today, Humedics has about 20 employees and scale up production development is ongoing. In May 2011, Humedics successfuly completed a second round of founding, with Charité Biomedical Fonds, KfW, VC Fonds Technologie Berlin and Ventegis Capital AG joining as investors.
Major award received in 2014